Get the Stockscreener App
964.04
3.31%
29.44
After Hours:
962.00
-2.04
-0.21%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $964.04, with a volume of 3.65M.
It is up +3.31% in the last 24 hours and up +1.16% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$934.60
Open:
$955.18
24h Volume:
3.65M
Relative Volume:
1.13
Market Cap:
$860.94B
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
34.70
EPS:
27.7808
Net Cash Flow:
$5.96B
1W Performance:
+9.23%
1M Performance:
+1.16%
6M Performance:
+11.90%
1Y Performance:
+21.59%
1-Day Range:
$950.97
$984.45
1-Week Range:
$850.51
$984.45
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
963.71 | 780.79B | 72.25B | 25.28B | 5.96B | 27.78 |
JNJ
Johnson Johnson
|
227.20 | 548.34B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
206.61 | 349.67B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
184.82 | 289.51B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
146.59 | 277.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
LLY Maintains Overweight by Cantor Fitzgerald -- Price Target Ra - GuruFocus
Lilly’s Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent - Investing.com
Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent - MarketBeat
BofA cuts Eli Lilly stock price target on valuation concerns - Investing.com
Raised guidance lifts Eli Lilly stock to fresh highs in strong session - Traders Union
Why is Eli Lilly stock surging today? - Investing.com
Eli Lilly and Co Stock (LLY) Moved Up by 4.44% on May 1: Facts Behind the Movement - TradingKey
Cantor Fitzgerald Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,230 - 富途牛牛
Eli Lilly Jumps As Earnings Beat Meets FDA Tightening Drug Compounding Rules - Benzinga
Eli Lilly and Company (NYSE:LLY) Q1 2026 Earnings Call Transcript - Insider Monkey
Cantor Fitzgerald raises Eli Lilly stock price target on guidance By Investing.com - Investing.com Canada
Lilly's obesity pill hits nearly 6,000 prescriptions in third week after launch - Reuters
Lilly Boosts Sales View to $85 Billion on Obesity-Drug Surge - Advisor Perspectives
Eli Lilly: The Most Expensive Stock in Pharma; and Maybe the Best - TradingView
Lilly’s new weight loss pill sees rising demand - Latest news from Azerbaijan
Goldman Sachs Adjusts PT on Eli Lilly and Co. to $1,283 From $1,260, Maintains Buy Rating - Moomoo
Leerink Partners Adjusts PT on Eli Lilly and Co. to $1,119 From $1,058, Maintains Outperform Rating - marketscreener.com
Why Eli Lilly and Company (LLY) is One of the Best Drug Stocks to Buy According to Analysts - Insider Monkey
Eli Lilly (LLY) Net Margin At 31.7% Tests Justification For 40.5x P/E Narrative - simplywall.st
Eli Lilly Capitalizes On Consumers' 'Love Affair' With Weight Loss Drugs: Gary Black Says Valuation 'Stil - Benzinga
Truist Securities: Eli Lilly's Incretin Portfolio Bolsters Multi-year Growth Potential; Estimates Updated - 富途牛牛
BMO Adjusts Model for Eli Lilly After 'Standout' Q1 - Moomoo
RBC Ups Estimates for Eli Lilly Post-Q1 Results; Outperform Rating Kept - 富途牛牛
With Earnings Booming, Can Lilly Hold Its Pharma Crown? - Moomoo
Eli Lilly Sales Surge 56% as Booming GLP-1 Demand Eclipses Lower Prices - The Daily Upside
US FDA proposes curbs on mass compounding of Novo, Lilly's weight-loss drugs - Reuters
Eli Lilly Q1 Revenue Hits $19.8B as GLP-1 Drugs Fuel Growth - Fitt Insider
GLP-1 Sales Continue to Lift Eli Lilly. Does That Make LLY Stock a Buy? - Barchart
Eli Lilly Earnings: Mounjaro/Zepbound's Massive Volume Growth More Than Counters Price Pressure - Morningstar
Eli Lilly and Co Options Spot-On: On April 30th, 89,364 Contracts Were Traded, With 341.58K Open Interest - Moomoo
Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com - 富途牛牛
Eli Lilly's Cardiometabolic Dominance Is Driving Stellar Growth and Supports a Wide Moat - Morningstar
Lilly’s Strong GLP-1 Results Signal Robust Market Growth for Novo Nordisk says Barclays - Investing.com
Eli Lilly (LLY) Q1 2026 Earnings Call Transcript - Fortune
Friday Five — Pfizer's LOE reprieve, Lilly's outsized earnings, Chiesi snaps up KalVista, and more… - FirstWord Pharma
More than 20k people on oral weight loss pill as Lilly ramps up access - IndyStar
Market movers: Qualcomm, Hertz, Eli Lilly, Royal Caribbean, 374Water… - Proactive financial news
Eli Lilly’s proven $19.8B quarter and what’s next - Rolling Out
Eli Lilly quells fears that its GLP-1 pill debut is off to a rocky start - Sherwood News
Why Eli Lilly stock just popped - MSN
High-flying Lilly delivers Q1 show of strength - The Pharma Letter
Eli Lilly (LLY) Q1 2026 Earnings Transcript - The Motley Fool
Lilly lifts profit forecast as surging demand for weight-loss drugs offsets pricing pressure - Reuters
Lilly earnings increase as Mounjaro, Zepbound sales continue rise - Inside INdiana Business
Lilly touts 'encouraging' early days for Foundayo obesity launch, even as GLP-1 pill appears to lag Novo's - Fierce Pharma
Why Eli Lilly Stock Just Popped - AOL.com
Confo Therapeutics Announces Phase 2 Clinical Trial Initiation by Lilly for Peripheral Pain Candidate, CFTX-1554 - Yahoo Finance
Eli Lilly Q1 2026 Earnings Call Transcript - Benzinga
Incretin boom lifts Eli Lilly (NYSE: LLY) Q1 profit 168% - Stock Titan
Why is Eli Lilly stock surging today? By Investing.com - Investing.com India
Lilly surges on earnings beat and raised guidance - Investing.com
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lilly Eli Co Stock (LLY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Montarce Lucas | EVP & CFO |
Feb 16 '26 |
Option Exercise |
0.00 |
368 |
0 |
16,418 |
| Custer Kenneth L. | EVP & President, Card Met Hlth |
Feb 16 '26 |
Option Exercise |
0.00 |
207 |
0 |
10,232 |
| Brown Adrienne S | EVP, President LLY Imm |
Feb 16 '26 |
Option Exercise |
0.00 |
391 |
0 |
5,312 |
| Yuffa Ilya | EVP&Pres, LLY USA&Global Capab |
Feb 01 '26 |
Option Exercise |
0.00 |
3,394 |
0 |
29,654 |
| Skovronsky Daniel | EVP, CS&PO & Pres. LRL |
Feb 01 '26 |
Option Exercise |
0.00 |
12,684 |
0 |
150,165 |
| Van Naarden Jacob | EVP,Pres LLY Oncology&HdCorpBD |
Feb 01 '26 |
Option Exercise |
0.00 |
4,108 |
0 |
24,670 |
| Ricks David A | President, Chair, and CEO |
Feb 01 '26 |
Option Exercise |
0.00 |
31,932 |
0 |
547,098 |
| Rau Diogo | EVP & CIDO |
Feb 01 '26 |
Option Exercise |
0.00 |
3,752 |
0 |
23,471 |
| Jonsson Patrik | EVP & President, LLY Int'l |
Feb 01 '26 |
Option Exercise |
0.00 |
3,930 |
0 |
57,581 |
| Hernandez Edgardo | EVP & Pres., Mfg. Operations |
Feb 01 '26 |
Option Exercise |
0.00 |
3,572 |
0 |
43,303 |
1.03%
2.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):